John Gustin Joins CSSi LifeSciences As Associate Director of Commercial Development

August 6, 2021 – John Gustin has joined CSSi LifeSciences as Associate Director of Commercial Development.

As Associate Director of Commercial Development at CSSi LifeSciences, his role will involve managing clients’ projects, which include regulatory filings and commercial planning.  Also, he will be connecting clients with strategic partners, such as investors or distributors.  Internally, he will be building out CSSi’s project management processes to assist in the scaling of the company

John Gustin says, “I joined CSSi LifeSciences because of the culture and the company’s mission of accelerating the development of new drugs and medical devices to patients who can benefit most.”

John is a trained breast cancer biologist and geneticist.  While at the Johns Hopkins University, he modeled and therapeutically targeted common cancer mutations.  John recently completed his MBA in Finance at Loyola University Maryland and had previously managed the Maryland Innovation Initiative, which funds university technologies and start-ups within the State.

Jim Sergi, President, CSSi LifeSciences, says, “John’s experience with life science start-ups and project management make him a great fit for CSSi LifeSciences as we look to scale our business.  He understands what life sciences companies need to succeed and will help us better serve our clients, which benefits the patients we serve.”  

About CSSi LifeSciences

CSSi LifeSciences is a global, innovative CRO and consulting group that specializes in advancing drugs and medical device technologies from discovery to commercialization. They offer customized solutions to propel life science technologies to market by mitigating risks, time, and cost, while increasing their client’s chances of success. Their insights, proven processes and strategic perspective deliver clear and actionable pathway to successful commercialization. Their integrated model provides optimum value-creation for early-stage and emerging growth companies.

For more information, please visit